IL154380A0 - Combination therapy for osteoporosis - Google Patents

Combination therapy for osteoporosis

Info

Publication number
IL154380A0
IL154380A0 IL15438096A IL15438096A IL154380A0 IL 154380 A0 IL154380 A0 IL 154380A0 IL 15438096 A IL15438096 A IL 15438096A IL 15438096 A IL15438096 A IL 15438096A IL 154380 A0 IL154380 A0 IL 154380A0
Authority
IL
Israel
Prior art keywords
osteoporosis
combination therapy
therapy
combination
Prior art date
Application number
IL15438096A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL154380A0 publication Critical patent/IL154380A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
IL15438096A 1996-02-28 1996-12-23 Combination therapy for osteoporosis IL154380A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28
IL12549396A IL125493A0 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis
PCT/IB1996/001462 WO1997031640A1 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis

Publications (1)

Publication Number Publication Date
IL154380A0 true IL154380A0 (en) 2003-09-17

Family

ID=21754846

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12549396A IL125493A0 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis
IL15438096A IL154380A0 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis
IL15437996A IL154379A0 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL12549396A IL125493A0 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15437996A IL154379A0 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis

Country Status (44)

Country Link
US (2) US6323232B1 (cs)
EP (3) EP1932543A3 (cs)
JP (2) JPH11504352A (cs)
KR (1) KR19990087337A (cs)
CN (5) CN1515258A (cs)
AP (3) AP974A (cs)
AR (2) AR005987A1 (cs)
AT (1) ATE405273T1 (cs)
AU (1) AU703285B2 (cs)
BG (1) BG64582B1 (cs)
BR (1) BR9612533A (cs)
CA (1) CA2247420C (cs)
CL (1) CL2004000119A1 (cs)
CO (1) CO4761063A1 (cs)
CZ (1) CZ297452B6 (cs)
DE (1) DE69637651D1 (cs)
DK (1) DK0883404T3 (cs)
DZ (1) DZ2186A1 (cs)
ES (1) ES2312169T3 (cs)
GT (2) GT199700009A (cs)
HN (1) HN1996000101A (cs)
HR (1) HRP970118A2 (cs)
HU (1) HUP9904123A3 (cs)
ID (1) ID19886A (cs)
IL (3) IL125493A0 (cs)
IS (1) IS4812A (cs)
MA (1) MA26420A1 (cs)
NO (2) NO323648B1 (cs)
NZ (1) NZ323456A (cs)
OA (1) OA10837A (cs)
PE (2) PE20011302A1 (cs)
PL (2) PL187962B1 (cs)
PT (1) PT883404E (cs)
RU (1) RU2190395C2 (cs)
SI (1) SI0883404T1 (cs)
SK (1) SK118398A3 (cs)
TN (1) TNSN97040A1 (cs)
TR (1) TR199801679T2 (cs)
TW (1) TW464496B (cs)
UA (1) UA69372C2 (cs)
UY (1) UY24472A1 (cs)
WO (1) WO1997031640A1 (cs)
YU (1) YU7797A (cs)
ZA (1) ZA971719B (cs)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU7349298A (en) 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
PL339297A1 (en) * 1997-09-09 2000-12-04 Procter & Gamble Method of inctrasing bone volume
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
HRP20000825A2 (en) * 1998-06-03 2001-12-31 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
EP0966968B1 (en) 1998-06-16 2004-05-06 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
HUP0102395A2 (hu) * 1998-06-16 2001-11-28 Pfizer Products Inc. Izom- és csontrendszeri gyengeség kezelésére alkalmas szelektív ösztrogén receptor modulátorok és növekedési hormon szekretagógok (GHS) kombinációját tartalmazó gyógyszerkészítmények
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
AP9901582A0 (en) * 1998-06-16 1999-06-30 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
KR20010083944A (ko) * 1998-11-03 2001-09-03 실버스타인 아써 에이. 신규 마크롤라이드 항생물질
AU3712000A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
DK1229909T3 (da) * 2000-06-01 2004-03-15 Watson Pharmaceuticals Inc Transdermal indgivelse af lasofoxifen
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
ES2233570T3 (es) * 2000-11-30 2005-06-16 Pfizer Products Inc. Composicion que contiene agonistas/antagosnistas de estrogenos y testosterona para tratar un descenso en el nivel de la hormona testosterona.
IL159996A0 (en) * 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
CZ2004118A3 (cs) * 2001-07-31 2004-09-15 Pfizer Products Inc. Farmaceutický prostředek, kit a způsoby zahrnující kombinaci činidla estrogenový agonist/antagonist, estrogenu a progestinu
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
RU2344819C1 (ru) * 2007-07-16 2009-01-27 Государственное образовательное учреждение дополнительного профессионального образования "Новокузнецкий государственный институт усовершенствования врачей Федерального агентства по здравоохранению и социальному развитию" Способ лечения посттравматического нейродистрофического синдрома
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2849910A1 (en) 2011-09-30 2013-04-04 Perio Sciences, Llc Antioxidant compositions for treatment of inflammation or oxidative damage
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
IL284875B (en) 2016-10-11 2022-07-01 Univ Duke Zofoxifene treatment for breast cancer
EP3773524B1 (en) 2018-04-10 2025-04-09 Duke University Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s
WO2019204985A1 (zh) * 2018-04-24 2019-10-31 深圳华大生命科学研究院 骨质疏松生物标志物及其用途
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (cs) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
DE3587956T2 (de) 1984-04-30 1995-05-24 Procter & Gamble Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3762617D1 (de) 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
ES2099245T3 (es) 1990-11-26 1997-05-16 Robert R Recker Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth).
JPH04312526A (ja) 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (cs) * 1993-07-22 1997-04-21 Lilly Co Eli
HUT75224A (en) * 1993-10-19 1997-04-28 Merck & Co Inc Combination of bisphosphonates and growth hormone secretagogues
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JPH10506091A (ja) 1993-11-09 1998-06-16 メルク エンド カンパニー インコーポレーテッド 成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−１ｈ−アゼピン類
AU684878B2 (en) 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
AU2695795A (en) 1994-06-13 1996-01-05 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
AU686019B2 (en) * 1994-09-09 1998-01-29 Procter & Gamble Company, The Phosphonates and parathyroid hormone for osteoporosis
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6100301A (en) 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
AU730856C (en) 1996-05-07 2001-11-15 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist
CA2257174A1 (en) 1996-05-31 1997-12-11 Novo Nordisk A/S Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
CA2247420A1 (en) 1997-09-04
AR060853A2 (es) 2008-07-16
IL125493A0 (en) 1999-03-12
AU1039897A (en) 1997-09-16
AP1179A (en) 2003-06-30
TW464496B (en) 2001-11-21
CN1209064A (zh) 1999-02-24
SK118398A3 (en) 2000-07-11
NO323648B1 (no) 2007-06-18
AP9700934A0 (en) 1997-04-30
ZA971719B (en) 1998-08-27
CN1515316A (zh) 2004-07-28
HUP9904123A3 (en) 2001-01-29
CN1515254A (zh) 2004-07-28
ID19886A (id) 1998-08-13
GT199700009AA (es) 1999-01-23
NO20063853L (no) 1998-08-27
EP1932543A3 (en) 2012-01-04
EP1932543A2 (en) 2008-06-18
US6323232B1 (en) 2001-11-27
GT199700009A (es) 1998-07-10
NZ323456A (en) 2001-03-30
HK1018210A1 (en) 1999-12-17
AR005987A1 (es) 1999-07-21
ATE405273T1 (de) 2008-09-15
DZ2186A1 (fr) 2002-12-02
IS4812A (is) 1998-07-28
UY24472A1 (es) 2000-09-29
AP2000001962A0 (en) 2000-12-31
CN1515317A (zh) 2004-07-28
HN1996000101A (es) 1997-06-26
PL187962B1 (pl) 2004-11-30
TNSN97040A1 (fr) 2005-03-15
AP975A (en) 2001-06-12
CA2247420C (en) 2011-02-15
RU2190395C2 (ru) 2002-10-10
JP2002308771A (ja) 2002-10-23
EP1236475A2 (en) 2002-09-04
DK0883404T3 (da) 2008-10-20
NO983936L (no) 1998-08-27
CZ297452B6 (cs) 2006-12-13
EP1236475A3 (en) 2003-11-05
AU703285B2 (en) 1999-03-25
CZ271898A3 (cs) 1999-06-16
ES2312169T3 (es) 2009-02-16
BG102726A (en) 1999-04-30
CN1515258A (zh) 2004-07-28
AP2002002661A0 (en) 2002-12-31
HRP970118A2 (en) 1998-04-30
BR9612533A (pt) 1999-07-20
BG64582B1 (bg) 2005-08-31
CO4761063A1 (es) 1999-04-27
UA69372C2 (en) 2004-09-15
EP0883404A1 (en) 1998-12-16
OA10837A (en) 2001-08-13
DE69637651D1 (en) 2008-10-02
IL154379A0 (en) 2003-09-17
MA26420A1 (fr) 2004-12-20
YU7797A (sh) 2000-10-30
AP974A (en) 2001-06-12
PE58998A1 (es) 1998-10-16
JPH11504352A (ja) 1999-04-20
NO983936D0 (no) 1998-08-27
HUP9904123A2 (hu) 2000-05-28
EP0883404B1 (en) 2008-08-20
US7255984B2 (en) 2007-08-14
CN1242813C (zh) 2006-02-22
PE20011302A1 (es) 2001-12-25
WO1997031640A1 (en) 1997-09-04
TR199801679T2 (xx) 2001-06-21
PL328831A1 (en) 1999-02-15
PL187219B1 (pl) 2004-06-30
SI0883404T1 (sl) 2008-10-31
CL2004000119A1 (es) 2005-02-11
PT883404E (pt) 2008-11-14
US20010009920A1 (en) 2001-07-26
KR19990087337A (ko) 1999-12-27

Similar Documents

Publication Publication Date Title
AP2000001962A0 (en) Combination therapy for osteoporosis
EG24678A (en) Combination therapy
IL112455A0 (en) Combination treatment for osteoporosis
ZA983176B (en) Therapeutic compounds
IL127306A0 (en) Combination therapy
ZA973209B (en) Therapeutic compounds.
EP0944635A4 (en) THERAPEUTIC DIPHOSPHONATE COMPOUNDS
GB9600143D0 (en) Therapeutic compounds
GB9700939D0 (en) Therapy
ZA971711B (en) Combination therapy to treat osteoporosis
GB9414909D0 (en) Osteoporosis apparatus
GB9716344D0 (en) Therapeutic compounds
PL320564A1 (en) Therapeutic set for treating osteoporosis
GB9626450D0 (en) Therapeutic compounds
GB2309083B (en) Osteoporosis apparatus
ZA977005B (en) Therapeutic uses
GB2321121B (en) Microprocessor
GB9708698D0 (en) Materials for therapy
GB9615350D0 (en) Hormone replacement therapy
GB9605466D0 (en) Therapy
GB9605525D0 (en) Therapy
GB9608372D0 (en) Therapeutic compounds
GB9608547D0 (en) Therapeutic compounds
GB9613017D0 (en) Therapeutic compounds
GB9700821D0 (en) Retarder unit